Biotech was big in 2019, but here's one record no one wanted to see broken: Most bankruptcies
With so much money and so many promises in biotech, something’s got to go bust. And in 2019, a lot did.
Although last year saw the second-most new drug approvals since 1997, it also saw more biotechs file for bankruptcy than in any year since 2011: 14, if you include disgraced giant Purdue Pharma. And that’s not including all the reverse mergers, which led to the disappearance of a host of failed biotechs: Proteon, NewLink, Conatus and Vical, among many others.
Bankruptcies in biotech are generally rare. Rarer still in the absence of a recession and with the industry still awash in cash. Like every year, a couple of biotechs simply ran out of money as their main asset fizzled. But other failures can be read as a stress-test for the industry’s blind spots and vulnerabilities in a year where federal investigators pursued opioid manufacturers and biotech execs joined public health experts in raising alarms about the state of antibiotics research. Those failures include:
- 3 companies facing opioid lawsuits
- 3 biotechs lost in the antibiotics desert
- 1 startup with a trendy pitch that caught the eye of reporters and investors but ultimately had little science behind it
- 2 biotech overcome by legal issues outside opioid peddling
The biotechs had collectively raised at least $2 billion since 2010, according to data from Deal Forma’s Chris Dokomajilar. We’ll go through each.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.